Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody Rituximab.

被引：0
|
作者：
Giagounidis, AAN
Anhuf, J
Schneider, P
Germing, U
Soehngen, D
Quabeck, K
Aul, C
机构：
[1] St Johannes Hosp, Med Klin 2, Duisburg, Germany
[2] Univ Dusseldorf, Med Klin A, Dusseldorf, Germany
[3] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[4] Haemato Onkol Schwerpunktpraxis, Duisburg, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2187
引用
收藏
页码：523A / 523A
页数：1
相关论文
共 50 条
  • [21] Severe idiopathic erythroblastic synartesis: successful treatment with the anti-CD20 monoclonal antibody rituximab
    Papakonstantinou, Georgios
    Loeffler, Helmut
    Haferlach, Torsten
    Brugger, Wolfram
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2010, 84 (06) : 547 - 549
  • [22] Treatment of idiopathic membranous nephropathy.: Is the anti-CD20 antibody rituximab a reasonable option?
    Busch, Martin
    Gerth, Jens
    Ott, Undine
    Schip, Andre
    Haufe, Christoph C.
    Groene, Hermann-Josef
    Wolf, Gunter
    MEDIZINISCHE KLINIK, 2008, 103 (07) : 519 - 524
  • [23] Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura.
    Delgado, J
    Bustos, JG
    Jimenez-Yuste, V
    Garcia, B
    de Paz, R
    Gracia, J
    Villar, A
    Quintana, M
    Hernandez-Navarro, F
    BLOOD, 2001, 98 (11) : 59B - 59B
  • [24] Successful use of anti-CD20 monoclonal antibody (Rituximab) for life-threatening refractory childhood immune thrombocytopenic purpura
    Bengston, KL
    Skinner, MA
    Ware, RE
    PEDIATRIC RESEARCH, 2002, 51 (04) : 241A - 241A
  • [25] Treatment of non-EBV-associated post-transplant lymphoproliferative disease with the anti-CD20 antibody rituximab.
    Oertel, SHK
    Krause, D
    Anagnostopoulos, I
    Jonas, S
    Hummel, MW
    Huhn, D
    Riess, HB
    BLOOD, 2000, 96 (11) : 731A - 731A
  • [26] Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
    Marzano, Angelo V.
    Fanoni, Daniele
    Venegoni, Luigia
    Berti, Emilio
    Caputo, Ruggero
    DERMATOLOGY, 2007, 214 (04) : 310 - 318
  • [27] Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)
    Herrmann, G
    Engert, A
    Hunzelmann, N
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 (03) : 602 - 603
  • [28] Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab)
    Heiligenhaus, Arnd
    Miserocchi, Elisabetta
    Heinz, Carsten
    Gerloni, Valeria
    Kotaniemi, Kaisu
    RHEUMATOLOGY, 2011, 50 (08) : 1390 - 1394
  • [29] A pilot study of anti-CD20 MoAb Rituximab in patients with refractory immune thrombocytopenic purpura (ITP).
    Saleh, MN
    Gutheil, J
    Moore, M
    Feinberg, B
    Bunch, P
    Butler, J
    Lavelle, P
    Kunkel, L
    Benyunes, K
    Grillo-Lopez, A
    LoBuglio, A
    BLOOD, 2000, 96 (11) : 252A - 253A
  • [30] A pilot study of anti-CD20 MoAb rituximab in patients with refractory immune thrombocytopenic purpura (ITP).
    Saleh, MN
    Moore, M
    Feinberg, B
    Bunch, P
    Butler, J
    Lavelle, P
    Kunkel, L
    Benyunes, K
    Grillo-Lopez, A
    LoBuglio, AF
    BLOOD, 2001, 98 (11) : 521A - 521A
12345